, /PRNewswire/ -- GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) on at as a sponsor to share keynote presentation, present Korean Scientist Awards and conduct global recruitment. The KASBP Symposium, hosted by the Korean American Society of Biopharmaceutical Professionals (KASBP), is an annual spring and fall event for Korean American scientists working in the U.S.
pharmaceutical and biotechnology industries to share the latest industry news and network. At the symposium, themed "Frontiers in Genomic Medicine", GC Biopharma will present its innovative new technology, the mRNA platform. GC Biopharma acquired a Development and Option agreement for Acuitas' LNP technology in 2022.
The company is building a new mRNA-LNP platform, selecting mRNA as one of the next-generation drug development platforms, secured its own technology and patents, and is actively conducting research to enter the clinical stage by applying this to various projects. Currently GCBP is conducting various studies, including the development of an mRNA flu vaccine and a treatment for the rare disease "SSADHD" Through KASBP, GCBP is committed to discovering promising young Korean professionals and Korean American researchers to nurture and support the next generation of experts who will lead the future of the life sciences and the pharmaceutical industries. At this symposium, GCBP plans to award "KASBP_GCBP Fellowship Award".
